FDA announces approval of Exact Sciences colorectal screening test The FDA said it approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer. The FDA added that the Centers for Medicare & Medicaid Services proposes to cover the Cologuard test once every three years for Medicare beneficiaries who meet certain criteria. Cologuard is manufactured by Exact Sciences. Reference Link
Exact Sciences checks show robust early adoption trends, says Jefferies Jefferies says its analysis of Exact Sciences' enrollment database indicates robust early adoption of Cologuard. The firm has increased conviction in its 2015 test volume forecasts and keeps a Buy rating on the stock with a $20 price target.
Exact Sciences volatility elevated Exact Sciences October call option implied volatility is at 88, November is at 78, January is at 71; compared to its 26-week average of 66 according to Track Data, suggesting large near term price movement.